Major Trial Finds Beta Blockers After Heart Attack Offer No Benefit for Most Patients

For roughly 40 years, beta blockers have been a near-automatic prescription after a heart attack, handed to patients as they leave the hospital. That near-universal practice is now under serious scrutiny following results from the REBOOT Trial, one of the largest and most rigorous studies ever conducted on post-heart attack medication.

The trial enrolled 8,505 patients from 109 hospitals across Spain and Italy. After discharge, participants were randomly assigned to either take beta blockers or avoid them, while both groups received all other current standard care including statins and antiplatelet drugs. Researchers tracked outcomes over a median of nearly four years, focusing on death, repeat heart attack, and hospitalization for heart failure.

The headline finding: beta blockers provided no statistically significant benefit for patients whose heart function remained preserved after an uncomplicated myocardial infarction. This is a critical distinction — the original evidence supporting beta blockers came from an era before modern interventions like rapid artery-reopening procedures and powerful adjunct therapies existed. The landscape of heart attack care has changed dramatically, and REBOOT suggests the evidence base for beta blockers hasn't kept pace.

Perhaps the most alarming finding involves women. Female patients taking beta blockers actually experienced a higher risk of death, repeat heart attack, or heart failure hospitalization compared to women who did not receive them. This sex-specific signal demands urgent follow-up and raises questions about whether women have been systematically exposed to a harmful rather than neutral treatment.

The practical implications are significant. If over 80% of uncomplicated heart attack patients are currently discharged on beta blockers without meaningful benefit, deprescribing could reduce side effects — including fatigue, low blood pressure, and sexual dysfunction — and simplify recovery regimens. Results were published in The New England Journal of Medicine and are expected to reshape international clinical guidelines. Patients currently on beta blockers post-heart attack should consult their cardiologist before making any changes.